Calamos Advisors LLC Sells 95,477 Shares of Novo Nordisk A/S $NVO

Calamos Advisors LLC decreased its position in Novo Nordisk A/S (NYSE:NVO) by 46.1% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 111,627 shares of the company’s stock after selling 95,477 shares during the period. Calamos Advisors LLC’s holdings in Novo Nordisk A/S were worth $7,704,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Lockheed Martin Investment Management Co. increased its stake in shares of Novo Nordisk A/S by 179.4% during the 2nd quarter. Lockheed Martin Investment Management Co. now owns 43,450 shares of the company’s stock worth $2,999,000 after purchasing an additional 27,900 shares during the last quarter. Unified Investment Management bought a new position in Novo Nordisk A/S during the second quarter valued at $692,000. Acadian Asset Management LLC increased its position in Novo Nordisk A/S by 15,919.9% in the first quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company’s stock worth $72,523,000 after buying an additional 1,038,137 shares during the last quarter. Guild Investment Management Inc. raised its stake in shares of Novo Nordisk A/S by 20.7% in the second quarter. Guild Investment Management Inc. now owns 36,995 shares of the company’s stock valued at $2,553,000 after buying an additional 6,345 shares during the period. Finally, Norden Group LLC lifted its position in shares of Novo Nordisk A/S by 216.3% during the 2nd quarter. Norden Group LLC now owns 96,332 shares of the company’s stock valued at $6,649,000 after buying an additional 65,877 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 2.3%

Shares of Novo Nordisk A/S stock opened at $49.12 on Friday. The company’s 50-day moving average price is $54.69 and its 200-day moving average price is $61.14. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 12-month low of $45.05 and a 12-month high of $112.52. The company has a market cap of $219.32 billion, a price-to-earnings ratio of 13.49, a PEG ratio of 2.33 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The business had revenue of $11.74 billion for the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. On average, equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on NVO. Barclays reissued an “equal weight” rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. Rothschild & Co Redburn upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 16th. Morgan Stanley lowered shares of Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and lowered their price target for the company from $59.00 to $47.00 in a research report on Monday, September 29th. Berenberg Bank raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Wednesday, September 17th. Finally, Dbs Bank upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, August 22nd. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $59.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.